SCHEMBL3638015

SCHEMBL3638015

Cc1cncn1CCCn1c(=S)[nH]c2sc3c(c2c1=O)CCC3

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
QPCT Q16769 16/20 1.00
RXFP1 Q9HBX9 3/20 0.61
RAD52 P43351 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3640158 0.98 QPCT (1.00) QPCTRXFP1RAD52
SCHEMBL3640787 0.97 QPCT (1.00) QPCTRXFP1RAD52
SCHEMBL3640847 0.97 QPCT (1.00) QPCTRXFP1RAD52
SCHEMBL5127426 0.86 QPCT (1.00) QPCTRXFP1
SCHEMBL5126367 0.83 QPCT (1.00) QPCT
SCHEMBL3640500 0.82 QPCT (1.00) QPCTRXFP1RAD52
SCHEMBL3638889 0.81 QPCT (1.00) QPCTRXFP1RAD52
SCHEMBL5126287 0.80 QPCT (1.00) QPCTRXFP1RAD52
SCHEMBL5127734 0.80 QPCT (1.00) QPCT
SCHEMBL5131168 0.80 QPCT (1.00) QPCTRXFP1RAD52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9034907-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2015-05-19 US claimed
EP-2160389-B1 THIOXOQUINAZOLINONE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS PROBIODRUG AG (DE) 2014-03-12 EP claimed
EP-2160389-A1 THIOXOQUINAZOLINONE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS Probiodrug AG (DE) 2010-03-10 EP claimed
US-20080267911-A1 NOVEL INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2008-10-30 US claimed
WO-2008128982-A1 THIOXOQUINAZOLINONE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS PROBIODRUG AG (DE) 2008-10-30 WO claimed
US-9034907-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2015-05-19 US disclosed
US-9034907-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2015-05-19 US disclosed
US-9034907-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2015-05-19 US disclosed
EP-2160389-B1 THIOXOQUINAZOLINONE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS PROBIODRUG AG (DE) 2014-03-12 EP disclosed
EP-2160389-A1 THIOXOQUINAZOLINONE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS Probiodrug AG (DE) 2010-03-10 EP disclosed
US-20080267911-A1 NOVEL INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2008-10-30 US disclosed
US-20080267911-A1 NOVEL INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2008-10-30 US disclosed
US-20080267911-A1 NOVEL INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2008-10-30 US disclosed
WO-2008128982-A1 THIOXOQUINAZOLINONE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS PROBIODRUG AG (DE) 2008-10-30 WO disclosed
WO-2008128982-A1 THIOXOQUINAZOLINONE DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS PROBIODRUG AG (DE) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080267911-A1 NOVEL INHIBITORS OF GLUTAMINYL CYCLASE GLS, GLS2, QPCT QPCT 3/4885RXFP1 171/4885RAD52 4718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.